文献速递肿瘤 PET/CT核素与放射性配体治疗

多发性骨髓瘤化疗后胸腺反弹出现68Ga-Pentixafor摄取增高

Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma.
PubMed 文献 · Clin Nucl Med · 2021-01-01

一例38岁新诊断多发性骨髓瘤男性患者,基线68Ga-Pentixafor PET/CT显示多发骨及骨髓病灶伴高摄取。化疗9周期后血清学完全缓解,复查PET/CT示原CXCR4阳性骨病灶摄取显著减低,但胸腺出现均匀高摄取、轮廓光滑、密度略增高,可能为化疗后胸腺增生所致。

要点

  • 68Ga-Pentixafor PET/CT可用于多发性骨髓瘤CXCR4表达评估。
  • 化疗后骨髓瘤病灶摄取减低与血清学缓解一致。
  • 胸腺反弹可表现为68Ga-Pentixafor均匀高摄取,需注意鉴别。

核心结论

  • 多发性骨髓瘤患者化疗后胸腺反弹可导致68Ga-Pentixafor PET/CT胸腺均匀高摄取,可能为胸腺增生所致。

研究设计与样本

  • 单例病例报告:38岁新诊断多发性骨髓瘤男性,基线及化疗9周期后行68Ga-Pentixafor PET/CT。

主要发现

  • 基线68Ga-Pentixafor PET/CT示多发骨及骨髓病灶伴强烈放射性摄取。
  • 化疗9周期后血清学完全缓解,复查PET/CT示原CXCR4阳性骨病灶摄取显著减低。
  • 复查PET/CT示胸腺强烈均匀摄取,轮廓光滑,密度略增高。

临床怎么用

  • 解读多发性骨髓瘤患者化疗后68Ga-Pentixafor PET/CT时,应识别胸腺反弹这一可能的高摄取原因,避免误判为病灶。

局限性

  • 单例病例报告,无法确定胸腺反弹的发生率及与其他治疗的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A 38-year-old man with newly diagnosed multiple myeloma underwent Ga-pentixafor PET/CT for baseline assessment. Ga-pentixafor PET/CT demonstrated multiple focal bone and bone marrow lesions with intense radioactivity. After 9 cycles of chemotherapy against multiple myeloma, the patient experienced serologically complete remission of myeloma. Consistently, the follow-up Ga-pentixafor PET/CT for PET response showed significantly reduced uptake in the previously chemokine receptor 4-positive bone lesions. However, intense and homogeneous uptake of Ga-pentixafor was noted in the thymus with a smooth contour and slightly increased density, which is possibly caused by thymic hyperplasia after chemotherapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pan Q, Luo Y, Cao X, et al. Increased Uptake of 68Ga-Pentixafor in Thymic Rebound After Chemotherapy in a Patient With Multiple Myeloma. Clin Nucl Med. 2021. PMID: 33181744. doi:10.1097/RLU.0000000000003375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。